Gene · 57697
Papers1,618
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 1,618
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. | Nat Genet | 2022 | 36456881 | PubTator, text mining | PubMed |
| The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. | BMC Urol | 2022 | 36451132 | PubTator, text mining | PubMed |
| Genomic disparities between cancers in adolescent and young adults and in older adults. | Nat Commun | 2022 | 36433963 | PubTator, text mining | PubMed |
| Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. | Cells | 2022 | 36428992 | PubTator, text mining | PubMed |
| Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru. | Cancers (Basel) | 2022 | 36428697 | PubTator, text mining | PubMed |
| The prevalence of germline pathogenic variants in Estonian colorectal cancer patients: results from routine clinical setting 2016-2021. | Front Genet | 2022 | 36425062 | PubTator, text mining | PubMed |
| Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations. | Cancer Manag Res | 2022 | 36411744 | PubTator, text mining | PubMed |
| Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. | Breast Cancer Res | 2022 | 36401316 | PubTator, text mining | PubMed |
| Whole exome sequencing identified a novel POT1 variant as a candidate pathogenic allele underlying a Li-Fraumeni-like family. | Front Oncol | 2022 | 36387164 | PubTator, text mining | PubMed |
| Meta-Analysis of EGF-Stimulated Normal and Cancer Cell Lines to Discover EGF-Associated Oncogenic Signaling Pathways and Prognostic Biomarkers. | Iran J Biotechnol | 2022 | 36381277 | PubTator, text mining | PubMed |
| Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. | Int J Mol Sci | 2022 | 36362142 | PubTator, text mining | PubMed |
| Contribution of Microhomology to Genome Instability: Connection between DNA Repair and Replication Stress. | Int J Mol Sci | 2022 | 36361724 | PubTator, text mining | PubMed |
| The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. | Cancers (Basel) | 2022 | 36358724 | PubTator, text mining | PubMed |
| Canonical and uncanonical pathogenic germline variants in colorectal cancer patients by next-generation sequencing in a European referral center. | ESMO Open | 2022 | 36356413 | PubTator, text mining | PubMed |
| Transcriptomic analysis of the human placenta reveals trophoblast dysfunction and augmented Wnt signalling associated with spontaneous preterm birth. | Front Cell Dev Biol | 2022 | 36353514 | PubTator, text mining | PubMed |
| A moving target for drug discovery: Structure activity relationship and many genome (de)stabilizing functions of the RAD52 protein. | DNA Repair (Amst) | 2022 | 36327799 | PubTator, text mining | PubMed |
| The N6-methyladenosine methyltransferase METTL16 enables erythropoiesis through safeguarding genome integrity. | Nat Commun | 2022 | 36307435 | PubTator, text mining | PubMed |
| Lynch Syndrome Identification in Saudi Cohort of Endometrial Cancer Patients Screened by Universal Approach. | Int J Mol Sci | 2022 | 36293153 | PubTator, text mining | PubMed |
| Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. | Gynecol Oncol | 2022 | 36273926 | PubTator, text mining | PubMed |
| TERRA and RAD51AP1 promote alternative lengthening of telomeres through an R- to D-loop switch. | Mol Cell | 2022 | 36265486 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57697/papers?page=16